BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...Treat acute migraine Submit NDA 2Q19 Cancer Prevention Pharmaceuticals Inc. / Mallinckrodt plc (NYSE:MNK) / Zeria...
BioCentury | Jun 23, 2017
Clinical News

IDMC recommends continuation of Cancer Prevention's Phase III FAP trial

...an ODC polymorphism and excretion of 4 urinary polyamines. The Tillotts Pharma AG subsidiary of Zeria...
...North America (see BioCentury, Feb. 1, 2016 ). Cancer Prevention Pharmaceuticals Inc. , Tucson, Ariz. Zeria...
...of 4 urinary polyamines Status: Phase III ongoing Milestone: NA Meghan Sullivan CPP-1X/sulindac DFMO/sulindac eflornithine/sulindac Cancer Prevention Pharmaceuticals Inc. Sucampo Pharmaceuticals Inc. Zeria...
BioCentury | May 11, 2017
Clinical News

Daiichi starts Phase III HEART-FID trial of iron therapy for heart failure

...has U.S. rights to the non-dextran IV iron replacement from Galenica Ltd. (SIX:VIFN). Galenica granted Zeria...
...treat iron deficiency anemia (see BioCentury, Aug. 19, 2013 ). Galenica Ltd. (SIX:VIFN), Bern, Switzerland Zeria...
...6-minute walk test (6MWT) Status: Phase III started Milestone: NA Alicia Parker Ferinject ferric carboxymaltose Injectafer Z-213 Daiichi Sankyo Co. Ltd. Galenica Ltd. Zeria...
BioCentury | Apr 11, 2016
Clinical News

Eflornithine/sulindac: Completed Phase III enrollment

...once daily vs. each of its components -- eflornithine or sulindac -- for 2 years. Zeria’s...
...product in North America (see BioCentury, Feb. 1). Cancer Prevention Pharmaceuticals Inc. , Tucson, Ariz. Zeria...
BioCentury | Aug 17, 2015
Company News

AstraZeneca, Zeria deal

...product sales of $53 million outside the U.S. in 2014. AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Zeria...
BioCentury | Jul 13, 2015
Company News

Numab, Zeria deal

...Numab granted Zeria’s Tillotts Pharma AG unit exclusive, worldwide rights to develop and commercialize antibodies against...
...to double digits. The companies declined to disclose financial details. Numab AG , Waedensil, Switzerland Zeria...
BioCentury | Apr 23, 2015
Distillery Therapeutics

Therapeutics: Arginase 1 (ARG1)

...compound to treat AD. (See "Arginine for Alzheimer's", page 13) Cancer Prevention Pharmaceuticals Inc. and Zeria...
BioCentury | Sep 15, 2014
Company News

Eisai, Zeria deal

...Eisai granted Zeria exclusive rights to develop and co-promote E3710 in Japan. Eisai will receive an...
...develop and co-promote E3710 in Japan. Eisai will receive an undisclosed upfront payment, plus royalties. Zeria...
...diseases. The partners could not be reached for details. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Zeria...
BioCentury | Sep 8, 2014
Clinical News

Ferinject ferric carboxymaltose: Phase IV data

...to the product from Galenica. In 2013, Galenica's Vifor Pharma Ltd. specialty pharma business granted Zeria...
...Aug. 19, 2013). Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Galenica Ltd. (SIX:GALN), Bern, Switzerland Zeria...
BioCentury | May 12, 2014
Clinical News

Injectafer ferric carboxymaltose regulatory update

...least 53 countries and is known as Ferinject outside North America. Last August, Galenica granted Zeria...
...Aug. 19, 2013). Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Galenica Ltd. (SIX:GALN), Bern, Switzerland Zeria...
Items per page:
1 - 10 of 107